XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.2
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Schedule of cash equivalents, restricted cash and marketable securities by security type

Cash equivalents, restricted cash and marketable securities by security type at June 30, 2019 were as follows:

 

 

 

 

 

 

 

Gross

 

 

Gross

 

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Included in cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

15,457

 

 

$

 

 

$

 

 

$

15,457

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted cash:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Certificate of deposit

 

$

270

 

 

$

 

 

$

 

 

$

270

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper (due in less than one year)

 

$

42,000

 

 

$

83

 

 

$

(1

)

 

$

42,082

 

Corporate notes (due in less than one year)

 

 

92,546

 

 

 

155

 

 

 

(5

)

 

 

92,696

 

Corporate notes (due in one to two years)

 

 

9,448

 

 

 

50

 

 

 

(1

)

 

 

9,497

 

 

 

$

143,994

 

 

$

288

 

 

$

(7

)

 

$

144,275

 

Cash equivalents, restricted cash and marketable securities by security type at December 31, 2018 were as follows:

 

 

 

 

 

 

 

Gross

 

 

Gross

 

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Included in cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

7,003

 

 

$

 

 

$

 

 

$

7,003

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted cash:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Certificate of deposit

 

$

269

 

 

$

 

 

$

 

 

$

269

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper (due in less than one year)

 

$

57,594

 

 

$

22

 

 

$

(29

)

 

$

57,587

 

Corporate notes (due in less than one year)

 

 

95,238

 

 

 

7

 

 

 

(118

)

 

 

95,127

 

Corporate notes (due in one to two years)

 

 

18,647

 

 

 

 

 

 

(65

)

 

 

18,582

 

 

 

$

171,479

 

 

$

29

 

 

$

(212

)

 

$

171,296

 

Schedule of cash equivalents and marketable securities with unrealized losses

Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at June 30, 2019 and December 31, 2018 were as follows:

 

 

 

Less Than 12 Months

 

 

12 Months or Longer

 

 

Total

 

 

 

 

 

 

 

Gross

 

 

 

 

 

 

Gross

 

 

 

 

 

 

Gross

 

 

 

Estimated

 

 

Unrealized

 

 

Estimated

 

 

Unrealized

 

 

Estimated

 

 

Unrealized

 

(In thousands)

 

Fair Value

 

 

Losses

 

 

Fair Value

 

 

Losses

 

 

Fair Value

 

 

Losses

 

As of June 30, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper (due in less than one year)

 

$

5,492

 

 

$

(1

)

 

$

 

 

$

 

 

$

5,492

 

 

$

(1

)

Corporate notes (due in less than one year)

 

 

11,318

 

 

 

(4

)

 

 

4,400

 

 

 

(1

)

 

 

15,718

 

 

 

(5

)

Corporate notes (due in one to two years)

 

 

1,053

 

 

 

(1

)

 

 

 

 

 

 

 

 

1,053

 

 

 

(1

)

 

 

$

17,863

 

 

$

(6

)

 

$

4,400

 

 

$

(1

)

 

$

22,263

 

 

$

(7

)

As of December 31, 2018:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper (due in less than one year)

 

$

22,628

 

 

$

(29

)

 

$

 

 

$

 

 

$

22,628

 

 

$

(29

)

Corporate notes (due in less than one year)

 

 

66,557

 

 

 

(82

)

 

 

14,221

 

 

 

(36

)

 

 

80,778

 

 

 

(118

)

Corporate notes (due in one to two years)

 

 

18,582

 

 

 

(65

)

 

 

 

 

 

 

 

 

18,582

 

 

 

(65

)

 

 

$

107,767

 

 

$

(176

)

 

$

14,221

 

 

$

(36

)

 

$

121,988

 

 

$

(212

)

Schedule of financial instruments measured at fair value on recurring basis

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018 and indicates the fair value category assigned.

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

Quoted Prices in

 

 

 

 

 

 

Significant

 

 

 

 

 

 

 

Active Markets for

 

 

Significant Other

 

 

Unobservable

 

 

 

 

 

 

 

Identical Assets

 

 

Observable Inputs

 

 

Inputs

 

 

 

 

 

(In thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of June 30, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

15,457

 

 

$

 

 

$

 

 

$

15,457

 

Commercial paper(2)

 

 

 

 

 

42,082

 

 

 

 

 

 

42,082

 

Corporate notes(2)(3)

 

 

 

 

 

102,193

 

 

 

 

 

 

102,193

 

Equity investment(4)

 

 

 

 

 

582

 

 

 

 

 

 

582

 

Total

 

$

15,457

 

 

$

144,857

 

 

$

 

 

$

160,314

 

As of December 31, 2018:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

7,003

 

 

$

 

 

$

 

 

$

7,003

 

Commercial paper(2)

 

 

 

 

 

57,587

 

 

 

 

 

 

57,587

 

Corporate notes(2)(3)

 

 

 

 

 

113,709

 

 

 

 

 

 

113,709

 

Equity investment(4)

 

 

 

 

 

585

 

 

 

 

 

 

585

 

Total

 

$

7,003

 

 

$

171,881

 

 

$

 

 

$

178,884

 

(1)

Included in cash and cash equivalents on our condensed balance sheets.

(2)

Included in current portion of marketable securities on our condensed balance sheets.

(3)

Included in noncurrent portion of marketable securities on our condensed balance sheets.

(4)

Included in other assets on our condensed balance sheets. See further discussion below of this equity investment.